Catalog No.
RHD10403
Species reactivity
Human
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Tested applications
ELISA: 1:10000, FCM: 1:200-1:400
Target
Folate receptor alpha, FOLR, FOLR1, Adult folate-binding protein, Folate receptor 1, FR-alpha, KB cells FBP, FBP, Ovarian tumor-associated antigen MOv18, Folate receptor, adult
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P15328
Applications
ELISA, FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3D95
Tumor-specific AAV delivery of interleukin-12 enhances antitumor immunity and safety in ovarian cancer xenograft mouse model., PMID:40529618
Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker., PMID:40508029
Personalized Treatment in Ovarian Cancer: A Review of Disease Monitoring, Biomarker Expression, and Targeted Treatments for Advanced, Recurrent Ovarian Cancers., PMID:40507303
Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer., PMID:40446758
FRα expression in advanced endometrial carcinoma: Clinicopathological, molecular, and prognosis correlates., PMID:40344965
Identification of potential cell surface targets in patient-derived cultures toward photoimmunotherapy of high-grade serous ovarian cancer., PMID:40205302
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial., PMID:40179908
FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma., PMID:40150910
A review of mirvetuximab soravtansine-gynx in folate receptor alpha-expressing platinum-resistant ovarian cancer., PMID:40126684
Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate., PMID:40121972
Evaluation of Laboratory-Derived Immunohistochemical Assays for Folate Receptor α Expression in Epithelial Ovarian Cancer and Comparison With a Companion Diagnostic., PMID:40073910
IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer., PMID:40029935
Mirvetuximab Soravtansine Induces Potent Cytotoxicity and Bystander Effect in Cisplatin-Resistant Germ Cell Tumor Cells., PMID:39996761
Expression-Dependent Tumor Pretargeting via Engineered Avidity., PMID:39704255
Development and evaluation of a single domain antibody targeting folate receptor alpha for radioligand therapy., PMID:39696571
Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers., PMID:39631181
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial., PMID:39617145
Deciphering Folate Receptor alphaGene Expression and mRNA Signatures in Ovarian Cancer: Implications for Precision Therapies., PMID:39596024
Folate Receptor Alpha-A Secret Weapon in Ovarian Cancer Treatment?, PMID:39595996
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary., PMID:39461270
Assessment of mirvetuximab soravtansine immunogenicity in patients with folate receptor alpha-positive ovarian cancer., PMID:39378056
Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimen., PMID:39307840
Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial., PMID:39068739
Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities., PMID:38941962
Folate Receptor Immunohistochemical Staining and Gynecologic Tumors: Initial Experience With 216 Cases., PMID:38914019
Folate Receptor Alpha Expression and the Tumor Immune Microenvironment in Patients with Cervical Cancer., PMID:38914017
Corrigendum: Therapeutic strategies targeting folate receptor α for ovarian cancer., PMID:38694498
Development of an FRα Companion Diagnostic Immunohistochemical Assay for Mirvetuximab Soravtansine., PMID:38282564
Folate Receptor Alpha-A Novel Approach to Cancer Therapy., PMID:38256120
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer., PMID:38101816
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer., PMID:38055253
Therapeutic strategies targeting folate receptor α for ovarian cancer., PMID:37711615
Extensive cytokine biomarker analysis in serum of Guillain-Barré syndrome patients., PMID:37221406
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer., PMID:37212825
Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes., PMID:36402875
Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1-antibody-drug conjugate., PMID:36149945
Integrated functional and spatial profiling of tumour immune responses induced by immunotherapy: the iPROFILER platform., PMID:35174321
Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies., PMID:34378534
Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer., PMID:34185411
Novel Anti-FOLR1 Antibody-Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells., PMID:33535554
Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope., PMID:33482584
Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix., PMID:33208671
Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients., PMID:33057068
Treatment of Folate Metabolism Abnormalities in Autism Spectrum Disorder., PMID:32892962
Correlation of folate receptor alpha expression with clinicopathological parameters and outcome in triple negative breast cancer., PMID:32829070
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody., PMID:32581215
Correlation between the expression of folate receptor alpha (FRα) and clinicopathological features in patients with lung adenocarcinoma., PMID:32450493
The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment., PMID:32409308
Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1., PMID:31497024
Folate Receptor α-Targeted 89Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer., PMID:31369274
For research use only. Not for human or drug use.
